Objective To assess the association between maternal cytomegalovirus (CMV) antibodies in mid-pregnancy and pre-eclampsia.
Introduction
Pre-eclampsia is a complication of pregnancy, characterised by the presence of elevated blood pressure and proteinuria occurring in a pregnant woman after 20 weeks of gestation.
1 Preeclampsia occurs in 2-7% of pregnant women and is a major cause of maternal and perinatal morbidity and mortality. 1 However, the underlying cause of pre-eclampsia is poorly understood.
Cytomegalovirus (CMV) infection is a frequent viral infection in human pregnancy,
with severe consequences for neonatal morbidity and long-term neurological development.
2
Following a primary infection, lifelong CMV latency is established in the host. Incidents of recurrent CMV infection in pregnancy are more common than primary infections, and most often caused by reactivation of latent virus, although reinfection with a different strain of CMV is also possible. 2 In seronegative women, primary CMV infection occurs in 1-4 % of pregnancies and transmits frequently to the fetus (30-40%) . 3 However, the majority of all congenital infections are estimated to be due to recurrent maternal infection, although the transmission rate is low (1%). 4 Infection by CMV in a pregnant woman may evoke mononucleosis-like symptoms, but most women are asymptomatic.
5
In early pregnancy, CMV infection can cause fetal death and miscarriage. [6] [7] It has also been hypothesized that early CMV infections may adversely affect placentation, with subsequent pregnancy complications, such as pre-eclampsia. [8] [9] Proper placentation depends on successful spiral artery remodeling ensured by optimal fetal trophoblasts invasion and angiogenic function of maternal Natural Killer (NK) cells in deciduas. 10 An established initial step of pre-eclampsia pathogenesis, is insufficient trophoblast invasion and NK cell interaction, leading to unconverted narrow spiral arteries and shallow placentation. 11 CMV infection induces impaired invasiveness in trophoblasts, direct activation of NK cells, and ! 5 may interfere with trophoblast interaction with NK cells by regulating trophoblast HLA expression. 8, 12 13 Hence, it is plausible that CMV infection in early pregnancy may underlie the inadequate spiral artery remodeling and shallow placentation of pre-eclampsia.
A small case-control study by Carreiras et al. reported an increased risk for developing pre-eclampsia in women with specific HLA-G alleles combined with CMV infection.
14 Previous studies investigating the potential association between CMV antibodies in pregnancy and development of pre-eclampsia are inconsistent. [15] [16] [17] Risk for developing pre-eclampsia has been shown associated with both 1) increased CMV immunoglobulin (Ig) G seroprevalence; 15 2) increased CMV IgG antibody levels; [15] [16] and 3) decreased CMV IgG seroprevalence. 17 Accordingly, the relation between CMV infection and pre-eclampsia remains uncertain.
Most previous studies have had limited power to make reliable estimates of association. The Norwegian Mother and Child Cohort Study (MoBa) is a prospective pregnancy cohort, with biological specimens and background data from more than 100 000 pregnancies, providing a unique opportunity with sufficient statistical power to investigate the association between CMV infection and pre-eclampsia. Using these prospectively collected data from the MoBa we, in the present study, wanted to explore the hypothesis that women who develop pre-eclampsia are more likely to have positive CMV IgG or IgM antibodies or higher CMV IgG antibody levels at 17-18 weeks of gestation than mothers who do not develop pre-eclampsia.
Methods

Subjects
The MoBa is a prospective population-based pregnancy cohort study conducted by the The inclusion criteria to our study were 1) present information about pre-eclampsia in the MBRN and 2) available plasma samples in the MoBa biobank (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . With consideration of economical expenses, 1500 pre-eclamptic and 1000 non-pre-eclamptic pregnancies were randomly selected as cases and controls, respectively. Fourteen case pregnancies were found not to fulfil the diagnostic criteria for pre-eclampsia, and these were excluded. Four control women were withdrawn by the MBRN because they discovered an error in the variable eclampsia for the year 2006. Twenty-one women had participated with two pregnancies in our sample (16 case women and five controls), and their latest registered pregnancy were excluded. The final study sample therefore included 1470 women with preeclamptic pregnancies and 991 women with non-pre-eclamptic pregnancies.
To assess exposure to CMV, plasma samples collected from the mothers at 17-18 weeks of gestation were examined. The 2461 plasma samples collected from the pregnant women were stored at -80°C. Levels of CMV IgM and IgG antibodies were determined by enzyme-linked immunosorbent assay (ELISA) (Medac, Hamburg, Germany). Seropositivity was defined according to the guidelines given by the manufacturer. The CMV IgM test used was an anti-IgM capture (µ-capture) ELISA, while the CMV IgG test was an indirect ELISA.
The CMV IgG levels were reported as Arbitrary Units per ml (AU/ml). Women with equivocal results (18 women for IgM antibodies (11 cases and seven controls), 57 women for IgG antibodies (22 cases and 35 controls)) were excluded from analysis. Determination of antibody status was conducted blinded; without knowledge of pre-eclampsia status.
We obtained information on the pre-eclampsia diagnosis (early/late onset), the mothers (maternal age at delivery, diabetes, chronic hypertension and civil status), the indexed pregnancies (parity, gestational age at birth, twin pregnancy) and the neonates (infant sex, birth weight) from the MBRN. Women's parity was dichotomised as nulliparous (no previous births) or parous (at least one previous birth). In the MBRN, gestational age at birth is calculated from routine ultrasonographic (US) measurements of biparietal diameter at 17- Norwegian or other. Women were asked "Do you smoke now (after you became pregnant)?".
We defined women as smokers ("sometimes" or "daily") or non-smokers ("no").
Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS 17) (SPSS Inc., Chicago, IL). We excluded the latest registered pregnancy of all women who participated with two pregnancies during the inclusion period. Student t test was used to compare differences in means between pre-eclamptic and non-pre-eclamptic
pregnancies for continuous variables. Mann-Whitney U-test was applied for comparison of continuous variables with a non-normal distribution. Differences in proportions were analyzed using Chi square statistics. Logistic regression was used to calculate crude and adjusted odds ratios (OR) with 95% confidence intervals (CI) for pre-eclamptic pregnancies in mothers who were seropositive for CMV, compared to CMV seronegative women. In these analyses, a variable was considered a confounder if it could theoretically be associated with both exposure (CMV) and outcome (pre-eclampsia). Thus, maternal age, parity and smoking in pregnancy were studied as possible confounding variables. In addition, confounding by parity (i.e. nulliparous vs. parous) was also studied in stratified analyses.
The study group comprised 90 twin pregnancies, 80 among cases and 10 among controls. Since the risk of pre-eclampsia triples in multiple pregnancies, 27 we explored antibody differences between cases and controls by first including twin pregnancies, then excluding them.
Two-sided P values lower than 0.05 was considered statistically significant. The number of cases and controls were based upon power calculations assuming a first-trimester CMV IgG seroprevalence of 70% among pregnant women in Norway. 28 Based upon these calculations, by including 1500 cases and 1000 controls, our study had 80% power to detect a 5 % higher proportion of CMV IgG antibody positive women in the case than in the control group (α = 0.05).
Results
Antenatal maternal data and their infants' status at birth are shown in Table 1 . The proportion of women with positive CMV IgG antibody status did not differ between cases (56.6%) and controls (60.5%) (P = 0.06) ( Table 2 ). After adjustment for maternal age at delivery, parity and smoking in pregnancy the OR of pre-eclampsia for women with IgG antibodies was 0.89
(95% CI 0.74-1.05; P = 0.17). When only CMV IgG seropositive women were considered, the level of CMV IgG was equal between cases and controls (P = 0.8) ( Table 2 ). The proportion of women seropositive for CMV IgM in the two groups was identical (1.2%) (P = 0.98). The adjusted OR for pre-eclampsia was 1.07 (95% CI 0.48-2.36; P = 0.87) for women seropositive for CMV IgM.
When twin pregnancies were excluded from the above analyses, the results were essentially unchanged (data not shown).
Among nulliparous women, the proportion of CMV IgG seropositive women was lower among cases (53.5%) than controls (59.8%) (P = 0.03). After controlling for maternal age and smoking, the OR for developing pre-eclampsia was 0.76 (95% CI 0.59-0.97; P = 0.03) for CMV IgG seropositive women compared with seronegative women. Regarding CMV IgM among nulliparous women, the proportions of seropositive women did not differ between the case and control groups (P > 0.6) (data not shown). Among parous women, there was no evidence to suggest a difference in CMV seropositivity between cases and controls (P > 0.5) (data not shown). Table 3 shows the number of women in each of the five subgroups of pre-eclampsia and some of their characteristics. Among women with late onset pre-eclampsia, 732 (56.5%) women were seropositive for CMV IgG compared to 578 (60.5%) of women without preeclampsia (P = 0.06) (Table 4) . When these analyses were stratified according to parity, nulliparous case women had a lower prevalence of CMV IgG seropositives (53.1%) than control women (59.8%) (P = 0.03). After adjustment for maternal age and smoking, nulliparous CMV IgG seropositive women had reduced OR for late onset pre-eclampsia (OR 0.75, 95% CI 0.58-0.96; P = 0.02). There were no differences in the proportions of CMV IgG seropositive women between any of the four other case subgroups and controls (Tables 4 and   !   11 5). When CMV IgG seropositive women were considered, there was no evidence to suggest a difference in levels of CMV IgG between subgroups of preeclampsia and controls (P > 0.09) (Table 4, Table 5 ). There were no differences in CMV IgM seropositive women between any of the five pre-eclampsia subgroups and controls (P > 0.15) (data not shown).
Discussion
In this large population-based study, we were not able to confirm our hypothesis that women who develop pre-eclampsia are more likely to have detectable CMV IgM antibodies at 17-18
weeks of gestation or to have higher prevalence or higher CMV IgG antibody levels than the control group. Thus, our results suggest that CMV infection in early pregnancy unlikely plays a role in development of pre-eclampsia.
The strengths of our study include the prospective recoding of perinatal data in the MBRN, the prospective, population based design of the MoBa, the large sample size and that all testing was blinded. Also, the proportion of CMV IgM seropositive women (1.2%) was within the expected range. 29 Misclassification in the MBRN, registering normal pregnancies as pre-eclampsia and vice versa, could potentially dilute the differences between cases and controls, and lead to an underestimation of a potential association between CMV infection and pre-eclampsia. However, we recently evaluated the validity of the pre-eclampsia diagnosis in the MBRN for the period 1967-2002 and found that pre-eclampsia could be confirmed in 88.3% of the pre-eclamptic pregnancies recorded in the MBRN (Liv Cecilie Vestrheim Thomsen, manuscript in prep.). The accuracy of the diagnosis is probably even higher in the latest decades, due to improved diagnostic criteria, and we therefore consider such misclassification to be of less significance in our study. Economic constraints limited the ! 12 total number of women available for analyses, and due to the aim of the study, the number of cases was prioritised. Importantly, this did not alter the statistical power of the analyses.
Multivariable analyses did not indicate confounding by maternal age, smoking and parity, although in analysis restricted to nulliparous women, the proportion of CMV IgG seropositive women was slightly lower in the pre-eclampsia group. This finding was also observed among the subgroup of women with late onset pre-eclampsia. Both findings are in the same direction, and coherent with the borderline non-significant difference in proportions of seropositive women between the pre-eclampsia and the control group (Table 2) . We are not aware of obvious biological explanations for these small differences. However, we emphasise that in this relatively large study population, P-values between 0.01 and 0.05 should be interpreted with caution. Even if the results could be due to multiple comparisons, we did not adjust for multiple comparisons, since the results were coherent, and since several authors have advised against such adjustment. [30] [31] [32] On the other hand, lack of statistical significant findings in some of the other subgroup analyses including early onset pre-eclampsia and those included in Table 5 should also be interpreted with caution due to a more limited statistical power in these analyses.
A limitation of our study is that antibodies to CMV were measured only at 17-18 weeks of gestation. Women seronegative at this time might have become infected later in pregnancy (seroconversion), and we cannot exclude that CMV infection may play a role later in pregnancy. However, the hypothesized impact of CMV infection on pre-eclampsia is that it may disturb the trophoblast invasion in first trimester. 14 If CMV infection played a major role in the pathogenesis of pre-eclampsia, it would be reasonable to expect a higher level of antibodies or a higher proportion of seropositive mothers in the pre-eclamptic group, even at 17-18 weeks of gestation.
Another potential limitation to our study is that a higher proportion of control women had equivocal results for IgG compared with cases, which could suggest selection bias.
However, since the largest proportion was in the control group, it seems unlikely that this could explain our results.
Several investigators have reported an association between maternal CMV infection and pre-eclampsia. [14] [15] [16] [17] Most of these studies had a limited number of case women. In the largest study to date, Xie et al. compared 78 women with pre-eclampsia to 109 normal pregnancy controls, and found higher levels of CMV IgG and that CMV IgG seropositivity was more common in the pregnancies complicated by pre-eclampsia (53% versus 27%, chisquared P < 0.01). 15 However, in contrast to our study population, their participants included several ethnic groups in which the seroprevalence of CMV is known to vary, 2 and the women were recruited from a single tertiary referral centre.
Although von Dadelszen and co-authors reported elevated levels of CMV IgG in a small group of women with early onset pre-eclampsia (n=9), their results agreed with ours in that mid-trimester women demonstrated no difference in the proportion of CMV IgG seropositive mothers between women who later developed pre-eclampsia and women with normal pregnancy outcomes. 16 A recent systematic review was also in agreement with our observations. 33 However, Trogstad et al. reported that women seronegative to CMV IgG in early pregnancy were at increased risk of developing pre-eclampsia, although not statistically significant (OR 1.6, 95% CI 0.8-3.2). 17 The authors discussed whether this finding might suggest susceptibility to acquire a primary CMV infection during pregnancy. Somewhat in consistence with their results, we found that nulliparous, CMV IgG seropositive women had a marginally lower OR of developing pre-eclampsia. The same finding was observed among women with late onset pre-eclampsia. However, the differences between the groups were 
Conclusion
In our large cohort study, we found neither increased levels of CMV IgG nor higher proportions of CMV seropositives (CMV IgG/IgM) among pregnant women who later developed pre-eclampsia. Thus, our findings do not suggest that CMV infection is an important cause of pre-eclampsia.
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Maternal data
Age at delivery (years) 29.9 ± 4.5 29. Data are n (%) or mean ± standard deviation; SGA, small for gestational age; Early onset preeclampsia, onset of pre-eclampsia before 34 weeks of gestation. 
